Hogan Lovells has advised Liberis and its lead investor Blenheim Chalcot on Nordic Capital’s acquisition of Liberis, aiming to merge it with Qred to enhance financing for small and medium-sized businesses.

Mayer Brown guided Omni Partners and Infoshare+ in acquiring DEF Software, enhancing their public sector software platform and expanding their market presence in infrastructure and asset management across the UK.

Hogan Lovells served as lead counsel for One Investment Management and its joint venture partners in acquiring The Other House portfolio, which includes three prime London sites to be transformed into a luxury wellness brand.

Latham & Watkins guided Frontier Tower Associates in acquiring Transcend Towers Infrastructure, adding 400 towers to its portfolio and enhancing its operational reach to over 6,500 sites across the Philippines.

Sidley Austin plans to become the anchor tenant of a new office building in Chicago’s Fulton Market, reflecting its commitment to growth and modern workspaces as construction begins next year.

DLA Piper guided Qualcomm Technologies in its participation in NEURA Robotics’ $1.4 billion Series C funding, aimed at enhancing robotics production and expanding AI applications, involving complex legal considerations across multiple jurisdictions.

Hogan Lovells has advised Pemberton Asset Management and HSBC UK on refinancing Nodor International, enhancing its growth strategy in premium darts and accessories through geographic expansion and new sales channels.

Baker McKenzie has guided Mitsui Chemicals in acquiring Ultradent Products for approximately $900 million, enhancing its presence in healthcare solutions. The deal is set to close in September 2026, pending regulatory approvals.

K&L Gates successfully guided StemCyte International, Ltd. in raising $14 million through its IPO on the Taiwan Stock Exchange, issuing 22.23 million new shares to support its cord blood banking services.

Gibson Dunn & Crutcher LLP has hired a former Ropes & Gray partner specializing in health regulatory and drug pricing, aiming to strengthen its advisory capabilities for pharmaceutical clients.